



Women's Health Newsletter No. 07/2016

Preeclampsia updates

10th October 2016

Contacts: Dina Metochi-Dix, Gabriella Bobba & Cyrill Wolf

With this Newsletter we would like to share with you some updates related to our Preeclampsia indication.

- Publications on the economic assessment of sFlt-1/PIGF ratio & the 2nd manuscript of PROGNOSIS.
- Useful materials, country initiatives & success stories.
- Upcoming conferences.

Publications

We are pleased to announce the publication of the evaluation of the economic impact of the sFlt-1/PIGF ratio in the management of suspected preeclampsia in the UK.

This was published as an open access version in the Ultrasound of Obstetrics and Gynaecology in June 2016:

The sFlt-1/PIGF ratio test in pre-eclampsia: an economic assessment for the UK

Manu Vatish, Torsten Strunz-McKendry, Martin Hund, Deirdre Allegranza, Cyrill Wolf and Caitlin Smare
([link](#)).

Key messages:

- The Elecsys® immunoassay sFlt-1/PIGF ratio can improve diagnostic accuracy and inform clinical decision-making in the prediction and management of preeclampsia.
- Use of the sFlt-1/PIGF ratio could reduce unnecessary hospitalizations and help ensure that women receive the care they require.
- Reducing unnecessary hospitalizations could generate an annual cost saving for the NHS of £24 million.

Useful links and materials

In September two webinar sessions were organized to present the findings of the above publication, focused on how the ratio could reduce unnecessary hospitalizations.

The slide deck of the webinar is now available on the intranet ([link](#); please note that this contains the links to the full slide decks of the HEcon publication and the UK NICE submission) and the recording can be accessed here ([link](#)).

If you require more information please contact Cyrill Wolf or Dina Metochi-Dix.

Country initiatives

Our UK affiliate has recently developed an infographic, which targets the healthcare finance stakeholder highlighting the value of the sFlt-1/PIGF in reducing healthcare costs while improving patient management. This proved to be a useful document in the initial engagement with this key stakeholder and is now available on the intranet as a pdf ([link](#)) for your reference.



Medical Affairs

Publications

In September two webinars were organized to present the **second publication of PROGNOSIS** data, focused on **time to delivery and preterm delivery**, recently published in Obstetrics & Gynecology ([link](#)). The slide decks are now available on the intranet ([short](#) and [extended](#) versions) and the recording can be accessed here ([link](#)).

Please note that the intended use of the Elecsys sFlt-1 and PIGF assays does not include prediction of time to delivery or preterm delivery, therefore we recommend that a **Medical** function presents and answers questions related to this publication.

Conferences

On October 23-26th, the 20th World Congress meeting of the International Society for the Study of Hypertension in Pregnancy ([ISSHP](#)) will take place in São Paulo, Brazil.

1,000 participants, including clinicians and scientists, are expected to attend a very interesting [program](#), which includes the **Roche Symposium “Predictive value of sFlt-1 / PIGF ratio in preeclampsia: clinical and economic implications”** with Dr Stefan Verlohren and Dr Manu Vatish.

Please find in this presentation ([link](#)) the details of the symposium and other oral and poster presentations about the Roche sFlt-1/PIGF ratio.

Success stories

We are happy to share with you the experience of our colleague Chiara Calvi, Medical Project Manager at Roche Italy, as information and inspiration for your local medical activities:

“The data and rumors generated by the PROGNOSIS study were the Trojan Horse to establish a contact with the most important Ob/Gyn experts in Italy. They recognized the innovation and value of having a new tool to manage preeclampsia. In fact, this complex syndrome is not very well known and is difficult to manage in everyday life, especially in Italy where there are a lot of hospitals not really specialized.

We decided to organize an Advisory Board in Roche, where the experts discussed about evidence, unmet needs and implementation opportunities. The discussion was so active and interesting that the members decided to publish the outcome, in order to provide guidance for implementation of the sFlt-1/PIGF ratio in clinical routine and for generation of additional evidence in new research and HEcon studies.

As Italian Medical Team, we are proud to share with all of you this publication:

“Italian Advisory Board: sFlt-1/PIGF ratio and preeclampsia, state of the art and developments in diagnostic, therapeutic and clinical management”

<http://www.sciencedirect.com/science/article/pii/S0301211516308922>

Thank you Chiara!



We hope the information in this Newsletter is useful for your local activities and we remain at your disposal to support you!

Please let us know if additional colleagues should be included in the distribution list. Any feedback on how to improve this Newsletter is very welcome!

Kind Regards

Your Pregnancy Care Global Team



Dina Metochi-Dix
International Product Manager
Pregnancy Care (ad interim)
Phone +41 41 792 53 56
dina.metochi-dix@roche.com



Gabriella Bobba
Senior Medical Affairs Manager
Phone +41 41 799 27 97
gabriella.bobba@roche.com



Cyrill Wolf
Market Access Manager
Phone +41 41 798 58 20
cyrill.wolf@roche.com